BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 16311119)

  • 1. Promoter hypermethylation profile of RASSF1A, FHIT, and sFRP1 in intracranial primitive neuroectodermal tumors.
    Chang Q; Pang JC; Li KK; Poon WS; Zhou L; Ng HK
    Hum Pathol; 2005 Dec; 36(12):1265-72. PubMed ID: 16311119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
    Chang Q; Ng HK
    Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor.
    Pang JC; Chang Q; Chung YF; Teo JG; Poon WS; Zhou LF; Kong X; Ng HK
    Hum Pathol; 2005 Jan; 36(1):36-43. PubMed ID: 15712180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
    Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
    Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
    Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
    Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas--implications for tumor biology and potential clinical utility.
    Frühwald MC; O'Dorisio MS; Dai Z; Tanner SM; Balster DA; Gao X; Wright FA; Plass C
    Oncogene; 2001 Aug; 20(36):5033-42. PubMed ID: 11526488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
    Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
    Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the RASSF1A gene in gliomas.
    Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
    Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
    Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
    Mühlisch J; Schwering A; Grotzer M; Vince GH; Roggendorf W; Hagemann C; Sörensen N; Rickert CH; Osada N; Jürgens H; Frühwald MC
    Oncogene; 2006 Feb; 25(7):1111-7. PubMed ID: 16186793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma.
    Inda MM; Muñoz J; Coullin P; Fauvet D; Danglot G; Tuñón T; Bernheim A; Castresana JS
    Histopathology; 2006 Apr; 48(5):579-87. PubMed ID: 16623784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation patterns in the Fhit regulatory region are tissue specific.
    Guler G; Iliopoulos D; Han SY; Fong LY; Lubet RA; Grubbs CJ; Huebner K
    Mol Carcinog; 2005 Jul; 43(3):175-81. PubMed ID: 15937960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
    Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.